Obinutuzumab in Follicular Lymphoma @nyulangone

Obinutuzumab in Follicular Lymphoma @nyulangone

obr

5 months
12 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone tells us about the design and outcomes of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma from ASH 2019.
Up Next Autoplay